Look out Gilead, Ab­b­Vie’s hep C com­bo comes with stel­lar da­ta, 8-week reg­i­men and a killer price

The FDA hand­ed Ab­b­Vie an OK and a help­ful la­bel on Thurs­day for its new com­bo ther­a­py for he­pati­tis C. And now they’re rolling it in­to an in­tense­ly com­pet­i­tive mar­ket with a low­ball price for the first 8-week reg­i­men that cov­ers all the ma­jor geno­types of the dis­ease.

In oth­er words, look out Gilead.

The drug’s com­mer­cial name is Mavyret, a com­bi­na­tion of pi­brentasvir com­bined with Enan­ta’s gle­capre­vir. Start­ing with the stan­dard 8-week course and then jump­ing to 12 and 16 weeks if nec­es­sary, re­searchers have tracked cure rates start­ing at 92% and ris­ing to 100%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER